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Abstract 
Background: Current international guidelines recommend 6–9 months of isoniazid (INH) preventive 
chemotherapy to prevent the development of active tuberculosis in children exposed to a 
susceptible strain of M tuberculosis. However, this is dependent on good adherence and 
retrospective studies have indicated that adherence to unsupervised INH preventive chemotherapy 
is poor.  
Aim: To prospectively document adherence to six months of unsupervised INH monotherapy and 
outcome in children with household exposure to an adult pulmonary tuberculosis index case.  
Methods: From February 2003 to January 2005 in two suburbs of Cape Town, South Africa, all 
children <5 years old in household contact with an adult pulmonary tuberculosis index case were 
screened for tuberculosis and given unsupervised INH preventive chemotherapy once active 
tuberculosis was excluded. Adherence and outcome were monitored.  
Results: In total, 217 index cases from 185 households were identified; 274 children <5 years old 
experienced household exposure, of whom 229 (84%) were fully evaluated. Thirty eight children 
were treated for tuberculosis and 180 received preventive chemotherapy. Of the children who 
received preventive chemotherapy, 36/180 (20%) completed ⩾5 months of unsupervised INH 
monotherapy. During the subsequent surveillance period six children developed tuberculosis: two 
received no preventive chemotherapy, and four had very poor adherence.  
Conclusion: Adherence to six months of unsupervised INH preventive chemotherapy was poor. 
Strategies to improve adherence, such as using shorter duration multidrug regimens and/or 
supervision of preventive treatment require further evaluation, particularly in children who are at 
high risk to progress to disease following exposure.  
 
 
 
1
  
 
 
 
 
 
 
 
 
 
 
 
A large percentage of children with household exposure to a sputum smear positive adult 
tuberculosis index case become infected with Mycobacterium tuberculosis.1–3 Following infection, 
the risk of developing disease is highest (20–50%) in very young (<2–3 years of age) and/or immune 
compromised children.4 These high risk children may experience rapid disease progression, which 
identifies them as the priority group to receive preventive chemotherapy.5 
Currently the World Health Organization (WHO) and the International Union against Tuberculosis 
and Lung Disease (IUATLD) recommend that all children <5 years of age who are in household 
contact with a sputum smear positive index case, should be actively traced and screened for 
tuberculosis.5,6 Six months of isoniazid (INH) is recommended as preventive chemotherapy once 
active tuberculosis has been excluded, because with good adherence, 6–9 months of INH 
monotherapy has proven efficacy to prevent tuberculosis in children infected with a susceptible 
strain of M tuberculosis.7,8,9,10 
Screening of children is difficult in resource limited settings,11 and several reports have shown that 
even when screening is performed, adherence to 6–9 months of unsupervised INH preventive 
chemotherapy is often very poor.12–16 These studies have been criticised, mainly for their 
retrospective methodology, and international guidelines have remained unchanged. However, 
adherence is a crucial component of any preventive chemotherapeutic regimen. We prospectively 
documented adherence to six months of unsupervised INH monotherapy, and outcome in children 
with household exposure to an adult pulmonary tuberculosis index case.  
What is already known on this topic 
 Young children, particularly those <3 years of age, are vulnerable to develop 
tuberculosis following household exposure to an infectious index case  
 With good adherence and following exposure to an index case with drug 
susceptible tuberculosis, 6–9 months of INH preventive chemotherapy provides 
good protection, although retrospective studies have reported poor adherence to 
unsupervised  
What this study adds 
 This is the first prospective study to investigate adherence to preventive INH 
chemotherapy in children; a special effort was made to limit selection bias  
 The study confirms that poor adherence is achieved using unsupervised INH 
preventive chemotherapy in children, putting them at risk to develop subsequent 
tuberculosis and emphasising the need to develop new preventive therapy 
strategies  
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METHODS 
Setting 
The study was conducted from February 2003 to January 2005 in two suburbs of Cape Town, South 
Africa. The estimated size of the study population was 36 334 (census data 2001), and the incidence 
of new smear positive tuberculosis was high (average notification rate of new bacteriologically 
confirmed tuberculosis 320/100 000).17 
Patients received antituberculosis treatment from two primary healthcare clinics. Facility based 
tuberculosis treatment registers were used to prospectively identify all new adult (>15 years) 
pulmonary tuberculosis cases. Household contacts were defined as those living at the same 
residential address as the adult index case at the time of diagnosis. A social worker visited the 
homes of new adult index cases and recorded the names and ages of all children resident at that 
address. According to South African National Tuberculosis control Programme (NTP) guidelines,18 
children with suspicious symptoms and all children <5 years old were invited for evaluation at the 
local primary healthcare clinic.  
Evaluation and treatment 
Evaluation included a tuberculin skin test (TST, 2TU PPD RT23 intradermally) and chest radiograph 
(antero-posterior and lateral views). A single expert read all chest radiographs in a standardised 
fashion and identified children with probable tuberculosis that required antituberculosis treatment. 
A rapid human immunodeficiency virus (HIV) screening test (Determine Rapid HIV test, Abbott) was 
offered, together with standard pre- and post-test counselling, if the mother was known to be HIV 
infected or if the child was diagnosed with tuberculosis.  
Antituberculosis treatment consisted of directly observed INH, rifampicin (RMP), and pyrazinamide 
(PZA) for two months, followed by INH and RMP for a further four months. Preventive 
chemotherapy consisted of unsupervised INH monotherapy for six months, with monthly collection 
of tablets from the clinic. Adherence was documented after completion of the six month preventive 
treatment period. Adherence was considered reasonable if tablets were collected for 5 months or 
more, poor if collection occurred for 2–4 months, and very poor if monthly tablets were collected 
once or twice only (treatment period <2 months). Surveillance was carried out during the study 
period and for an additional 6 months after study enrolment stopped, to document children who 
were subsequently diagnosed with tuberculosis.  
Parents gave written informed consent for study participation and approval was obtained from the 
City of Cape Town Health Department, local health committees, and the institutional review board 
of Stellenbosch University.  
RESULTS 
In total, 217 adult index cases from 185 households were identified, of whom 171 (79%) were 
sputum smear positive, 17 (8%) were culture positive, and 29 (13%) were diagnosed by chest 
radiography. Enumeration of household contacts <5 years of age identified 274 children. 
Demographics and tuberculosis screening results are reflected in table 1. No mothers were known 
to be HIV infected; 89.5% (34/38) of the children diagnosed with tuberculosis were tested for HIV 
and none tested positive. Of the 38 children diagnosed with tuberculosis after the initial screening 
tests, 31 (81.6%) were <3 years of age.  
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Adherence to antituberculosis treatment and unsupervised INH preventive chemotherapy is 
reflected in table 2. No side effects (peripheral neuropathy or liver damage) were reported or 
observed with the use of INH monotherapy. The outcome of children treated for tuberculosis was 
good; one child was lost to follow up. Of the 236 children without signs of tuberculosis at initial 
screening, six (3%) subsequently developed tuberculosis: 2/56 (4%) who received no preventive 
chemotherapy, and 4/130 (3%) with very poor adherence. In total, 36/44 (81.8%) children 
diagnosed with tuberculosis were <3 years of age: 31/38 (81.6%) diagnosed at initial screening and 
5/6 (83.3%) who developed tuberculosis subsequently. 
DISCUSSION 
The most striking observation was the poor adherence to six months of unsupervised INH 
preventive chemotherapy in the study setting. Nearly 80% of household contacts <5 years old 
either received no preventive treatment at all or showed very poor adherence (<2 months). 
Frequently the only criterion considered when evaluating the potential public health value of a 
chemotherapeutic intervention is its efficacy under ideal trial conditions, while little emphasis is 
placed on “real life” operations research. Both efficacy, which is usually established under 
conditions of optimal adherence, and actual adherence in “real life” are essential elements that 
determine the ultimate effectiveness of the intervention.  
Poor adherence to unsupervised INH monotherapy is not a novel finding,11–15 but this study 
incorporated some design elements that were absent in most previous studies. It was a prospective 
study conducted in an endemic area with active tracing of all child contacts. This allowed us to 
accurately document the total number of child contacts, the number evaluated, and the number 
who received preventive chemotherapy. Previous studies usually documented adherence only in 
the children who turned up for screening or in whom preventive chemotherapy was initiated, which 
imposes a significant selection bias. The finding that 24% of all children <5 years of age with 
household exposure to a tuberculosis index case were not even offered preventive chemotherapy, 
is almost certainly a gross underestimate of the situation in most endemic areas. The study area 
was well resourced, had easy access to TST and chest x ray screening tests, and additional effort 
was made during the study period to trace and invite all children for screening. A survey performed 
in Malawian hospitals showed that child contacts were screened for tuberculosis in only 12% of 
hospitalised adult tuberculosis cases.11 
The fact that 82% of children who received antituberculosis treatment were <3 years of age, 
illustrates the particular importance of providing preventive treatment to this high risk group. The 
pre-chemotherapy literature that documented the natural history of disease emphasises the 
vulnerability of this age group,4 and more recent reports from India also indicate that children <3 
years of age are at highest risk to develop severe disease manifestations.19 In addition, in children 
⩾3 years of age the majority of transmission in endemic areas occurs outside the household.20,21 
Therefore, in resource limited settings where tuberculosis services are overstretched even without 
offering screening or preventive chemotherapy to children in household contact with an adult index 
case, it seems warranted to focus the provision of preventive chemotherapy on those children who 
are at highest risk to progress to disease following household exposure (<3 years and/or immune 
compromised).4,5 This seems like the most realistic way to improve access to preventive 
chemotherapy for those children who are most likely to benefit.  
A three month preventive chemotherapy regimen of INH and RMP has been evaluated in children 
and appears equally efficacious as 6–9 months of INH monotherapy,22,23 while significantly better 
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adherence has been reported with this short duration multidrug preventive regimen.12,22 In theory, 
RMP and PZA are best suited for the treatment of latent infection as they are the two most 
important sterilising drugs available.22 Although this combination has proven efficacy in animal 
models,24 adverse reactions in adult patients have limited initial enthusiasm.25 However, these 
adverse reactions have not been recorded in children,26 and the standard three drug combination 
of INH, RMP, and PZA is generally well tolerated. Further studies are required to establish the 
efficacy and safety of short course multidrug preventive regimens, but this seems like the most 
promising alternative, both to reduce the risk of INH resistance and to improve treatment 
adherence.  
In general, children contribute little to the creation of the drug resistance problem, although they 
may suffer a great deal as a result of it. Children usually have pauci-bacillary disease and therefore 
their chance of acquiring random INH resistance is small and they rarely contribute to disease 
transmission within the community. The main factor that influences children’s risk to become 
infected with an INH resistant strain is the prevalence of transmitted INH resistance within the 
community. Drug resistance patterns among children provide an accurate reflection of transmitted 
drug resistance within a community. A recent survey of drug resistance patterns among children 
from areas surrounding and including the study setting, showed that 12.4% of all children with 
culture positive disease were infected with an INH resistant strain.27 The safety of persisting with 
INH monotherapy as the preventive chemotherapy option of choice should be questioned in similar 
settings. In addition to child safety concerns it is also conceivable that INH monotherapy will fail to 
eradicate INH resistant bacilli, providing them with a selective advantage to produce adult-type 
(reactivation) disease later in life, contributing to increased transmitted drug resistance within the 
community.  
The study’s main limitation is the fact that it was done in a single community, although the study 
community is thought to be representative of the situation in many endemic areas. No intervention 
was performed to improve adherence in children who defaulted, as the study aimed to document 
adherence in “real life”. Preventive chemotherapy was provided in the routine fashion by the local 
clinic and adherence was documented only after completion of the six month treatment period. In 
addition, reasons for poor adherence were not well documented, but in limited parent interviews 
the issue of parental risk perception featured prominently. Parents who discontinued preventive 
chemotherapy often recounted how children from family and/or friends who also defaulted came 
to no harm. As children who receive preventive chemotherapy are completely healthy, healthcare 
personnel need to pay particular attention that the concept of risk reduction is effectively 
conveyed, which may strengthen the argument to focus preventive chemotherapy in endemic areas 
primarily on high risk children.  
In conclusion, this study confirms that adherence to six months of unsupervised INH preventive 
chemotherapy is poor. It emphasises the need to develop chemoprophylaxis strategies with 
improved adherence, such as short duration multidrug regimens and/or utilising treatment 
supervision, particularly in children who are at high risk of disease progression following 
exposure.28 
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 Tables 
Table 1  
Demographics and tuberculosis screening results in children <5 years old in household contact with 
an adult pulmonary tuberculosis index case (n = 274)  
 No. (%) 
 
Gender   
Male 129 (47) 
  
Age   
<3 years of age 178 (45) 
  
HIV   
Mother known HIV+ 0 
Children tested 34 (12) 
Children positive 0/34 
  
TST   
Tested 243 (89) 
Positive (⩾10 mm) 122/243 (50) 
  
Screening   
Not screened 14 (5) 
Partially screened* 31 (11) 
Fully screened† 229 (84) 
  
Treatment   
Treated for tuberculosis 38 (14) 
Preventive chemotherapy 180 (66) 
No treatment 56 (20) 
HIV, human immunodeficiency virus; TST, tuberculin skin test. 
*Partially screened: either a TST or chest radiograph performed and read. 
ully screened: both a TST and chest radiograph performed and read. 
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Table 2  
Adherence to antituberculosis treatment and preventive chemotherapy, and outcome according to 
preventive chemotherapy adherence 
 
Adherence (%) 
Not given Very poor Poor Reasonable 
Treatment regimen      
TB treatment (n = 38) 0 1 (3) 3 (8) 34 (89) 
Preventive chemotherapy 6H (n = 236) 56 (24) 130 (55) 14 (6) 36 (15) 
     
Outcome      
Preventive chemotherapy group TB within 6/12 2/56 (4) 4/130 (3) 0 0 
Very poor: received <2 months of therapy. 
Poor: received 2–4 months of therapy. 
Reasonable: received >4 months of therapy. 
TB, tuberculosis. 
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